Abstract
Respiratory particles produced by breathing, coughing, and speaking or generated during medical procedures serve as important routes for disease transmission. Characterising the number of particles generated as well as their size distribution is fundamental for guiding policy on infection control. However, sampling such particles carries inherent challenges. Respiratory particles are polydisperse in size, temporally and spatially variable, and emitted in very low concentrations, usually lower than the pre-existing aerosol concentration in indoor environments. In addition, they are typically emitted in a highly dynamic, warm and humid jet, leading to further rapid processes, such as dispersion and evaporation. Here, we discuss important considerations for sampling respiratory aerosol, focusing on sampling particles < 20 µm in diameter. Instruments capable of counting single-particles within this size range are commercially available. We provide recommendations for experimental protocols and demonstrate the limitations behind such approaches. We highlight the importance of a measurement space with as low a background aerosol concentration as possible, and of sampling for as long as possible to enable accurate quantitation of the size distribution of an aerosol plume. This is particularly important for the larger particles (> 5µm diameter) that are so low in concentration that they may require hours of sampling time to be accurately quantified. We explore the relationship between the flow rates of the exhalation and the sampling instrument and the consequent quantification of particle flux. We also discuss the transport and evaporation dynamics of liquid particles within respiratory jets, and their impacts on conducting aerosol sampling studies.
| Original language | English |
|---|---|
| Pages (from-to) | 160-175 |
| Number of pages | 16 |
| Journal | Aerosol Science and Technology |
| Volume | 56 |
| Issue number | 2 |
| Early online date | 25 Oct 2021 |
| DOIs | |
| Publication status | Published - 25 Oct 2021 |
Bibliographical note
Funding Information:The AERATOR study was funded by an NIHR-UKRI rapid rolling grant (COV0333). H.E.S. and J.A. are supported by the PERFORM 2 study, funded by UKRI-EPSRC (EP/V050516/1). B.R.B. is supported by the Natural Environment Research Council (NE/P018459/1). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, UKRI, or the Department of Health. The authors acknowledge the AERATOR group, which consists of (in alphabetical order): Arnold, D; Brown, J; Bzdek, B; Davidson, A; Dodd, J; Gormley M; Gregson, F; Hamilton, F; Maskell, N; Murray, J; Keller, J; Pickering, A.E; Reid, J; Sheikh, S; Shrimpton, A. We acknowledge the Working Group for The Investigation of ParticulatE Respiratory Matter Release During perFormance and Exercise to infOrm Guidance in the SARS-CoV-2 PandeMic (PERFORM 2) for useful discussions.
Publisher Copyright:
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Research Groups and Themes
- AERATOR
- Physical & Theoretical
Fingerprint
Dive into the research topics of 'Analytical Challenges when Sampling and Characterising Exhaled Aerosol'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver